

- Siegel R, Naishadham D, Jemal A. Cancer statistics. *CA Cancer J Clin* 2012; 62:10–29.
- National Cancer Institute. SEER Stat Fact Sheets: Kidney and Renal Pelvis Cancer. SEER Web site. <http://seer.cancer.gov/statfacts/html/kidrp.html#risk>. Accessed May 2, 2012.
- Clague J, Lin J, Cassidy A, et al. Family history and risk of renal cell carcinoma: Results from a case-control study and systematic meta-analysis. *Cancer Epidemiol Biomarkers Prev* 2009;18:801–807.
- Deng FM, Melamed J. Histologic variants of renal cell carcinoma: Does tumor type influence outcome? *Urol Clin North Am* 2012;39:119–132.
- Lonsler RR, Glenn GM, Walther M, et al. von Hippel–Lindau disease. *Lancet* 2003;361:2059–2067.
- Charlesworth M, Verbeke CS, Falk GA, et al. Pancreatic lesions in von Hippel–Lindau disease? A systematic review and meta-synthesis of the literature. *J Gastrointest Surg* 2012;16:1422–1428.
- Latif F, Tory K, Gnarr J, et al. Identification of the von Hippel–Lindau disease tumor suppressor gene. *Science* 1993;260:1317–1320.
- Gnarr J, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. *Nat Genet* 1994;7:85–90.
- Shuin T, Kondo K, Torigoe S, et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel–Lindau tumor suppressor gene in primary human renal cell carcinomas. *Cancer Res* 1994;54:2852–2855.
- Schimke RN, Collins DL, Stolle CA. Von-Hippel Lindau Syndrome. GeneReviews at GeneTests: Medical Genetics Information Resource (website) <http://www.genetests.org>. Updated December 22, 2009. Accessed April 11, 2012.
- Birt AR, Hogg GR, Dube WJ. Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. *Arch Dermatol* 1977;113:1674–1677.
- Nickerson ML, Warren MB, Toro JR, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt–Hogg–Dube syndrome. *Cancer Cell* 2002;2: 157–164.
- Pavlovich CP, Grubb RL 3rd, Hurley K, et al. Evaluation and management of renal tumors in the Birt–Hogg–Dube syndrome. *J Urol* 2005;173: 1482–1486.
- Schmidt LS, Nickerson ML, Warren MB, et al. Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt–Hogg–Dube syndrome. *Am J Hum Genet* 2005;76:1023–1033.
- Pavlovich CP, Walther MM, Eyler RA, et al. Renal tumors in the Birt–Hogg–Dube syndrome. *Am J Surg Pathol* 2002;26:1542–1552.
- Zbar B, Alvord WC, Glenn G, et al. Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt–Hogg–Dube syndrome. *Cancer Epidemiol Biomarkers Prev* 2002;11:393–400.
- Toro JR, Pautler SE, Stewart L, et al. Lung cysts, spontaneous pneumothorax, and genetic associations in 89 families with Birt–Hogg–Dube syndrome. *Am J Respir Crit Care Med* 2007;175:1044–1053.
- Houweling AC, Gijzen LM, Jonker MA, et al. Renal cancer and pneumothorax risk in Birt–Hogg–Dube syndrome; an analysis of 115 FLCN mutation carriers from 35 BHD families. *Br J Cancer* 2011;105:1912–1919.
- Singer EA, Bratslavsky G, Middelton L, et al. Impact of genetics on the diagnosis and treatment of renal cancer. *Curr Urol Rep* 2011;12:47–55.
- Toro JR, Wei MH, Glenn GM, et al. BHD mutations, clinical and molecular genetic investigations of Birt–Hogg–Dube syndrome: A new series of 50 families and a review of published reports. *J Med Genet* 2008;45:321–331.
- Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. *Nat Genet* 1997;16:68–73.
- Fischer J, Palmado G, von Knobloch R, et al. Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours. *Oncogene* 1998;17:733–739.
- Zhuang Z, Park WS, Pack S, et al. Trisomy 7—harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinoma. *Nat Genet* 1998;20:66–69.
- Lindor NM, Dechet CB, Greene MH, et al. Papillary renal cell carcinoma: Analysis of germline mutations in the MET proto-oncogene in a clinic-based population. *Genet Test* 2001;5:101–106.
- Wei MH, Toure O, Glenn GM, et al. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. *J Med Genet* 2006;43:18–27.
- Gardie B, Remenieras A, Kattygnarath D, et al. Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma. *J Med Genet* 2011;48:226–234.
- Vanharanta S, Buchta M, McWhinney SR, et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. *Am J Hum Genet* 2004;74:153–159.
- Henderson A, Douglas F, Perros P, et al. SDHB-associated renal oncocytoma suggests a broadening of the renal phenotype in hereditary paragangliomatosis. *Fam Cancer* 2009;8:257–260.
- Ricketts C, Woodward ER, Killick P, et al. Germline SDHB mutations and familial renal cell carcinoma. *J Natl Cancer Inst* 2008;100:1260–1262.
- Ricketts CJ, Forman JR, Rattenberry E, et al. Tumor risks and genotype–phenotype–proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. *Hum Mutat* 2010;31:41–51.
- Srirangalingam U, Walker L, Khoo B, et al. Clinical manifestations of familial paraganglioma and pheochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers. *Clin Endocrinol (Oxf)* 2008;69: 587–596.
- Gill AJ, Pachter NS, Chou A, et al. Renal tumors associated with germline SDHB mutation show distinctive morphology. *Am J Surg Pathol* 2011; 35:1578–1585.
- Rouprêt M, Yates DR, Comperat E, et al. Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (Lynch syndrome) tumor spectrum. *Eur Urol* 2008;54:1226–1236.
- Crockett DG, Wagner DG, Holmäng S, et al. Upper urinary tract carcinoma in Lynch syndrome cases. *J Urol* 2011;185:1627–1630.
- van der Post RS, Kiemeny LA, Ligtenberg MJ, et al. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. *J Med Genet* 2010;47:464–470.
- VHL Alliance. A list of VHL specialty clinics in the United States and other countries. www.vhl.org. Accessed September 3, 2014.